Valneva reports positive results for its COVID-19 vaccine candidate
The Peninsula
PARIS: Valneva reported positive Phase III results on Monday for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001, a boost for the French biotech company after Britain cancelled a big deal to buy its shot.
Valneva said its latest trial which was conducted on 4,012 participants aged 18 years and older across 26 trial sites in Britain and showed the vaccine prompted a stronger immune response and fewer side-effects than AstraZeneca's shot.
Valneva is among a handful of vaccine developers testing their vaccines against one that's already been approved by a regulator rather than giving volunteers a dummy placebo as shots become more available.
More Related News